Dupilumab Safety in Children with Chronic Spontaneous Urticaria

This study focuses on understanding how the drug dupilumab works in the bodies of children between the ages of 2 and 12 who have a condition called chronic spontaneous urticaria (CSU) that isn't getting better with standard allergy medications. CSU causes uncomfortable and persistent hives or welts on the skin. The main goal is to examine how the drug is processed in the body (known as pharmacokinetics) and to ensure it is safe for use in this young age group. Finding effective treatment options for children who suffer from such persistent symptoms is important for improving their quality of life. Participants in this study are treated with dupilumab over a 24-week period. The drug is administered, and blood samples are taken at specific times to measure the concentration of the drug in the body, particularly at the 12th and 24th weeks. This helps researchers understand how the drug behaves over time. The study includes a screening period of up to 4 weeks, followed by 6 visits over the course of the study. There is also a 12-week follow-up after treatment ends to monitor any long-term effects. This structured approach ensures a thorough evaluation of the drug's safety and how well it works in managing CSU symptoms.